TTK HealthcareBOM:507747 +1.47%72 ROE % is 7.81% as of Mar. 2026, which is 19% below its 10-year median of 9.68. GuruFocus rates BOM:507747 with a GF Score™ of 72/100 and a GF Value™ of ₹1,452.52 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 935 Drug Manufacturers companies, TTK Healthcare ranks better than 50.05% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. TTK Healthcare's annualized net income for the quarter that ended in Mar. 2026 was ₹870 Mil. TTK Healthcare's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹11,149 Mil. Therefore, TTK Healthcare's annualized ROE % for the quarter that ended in Mar. 2026 was 7.81%.
The historical rank and industry rank for TTK Healthcare's ROE % or its related term are showing as below:
BOM:507747'
s ROE % Range Over the Past 10 Years
Min: 4.92 Med: 9.68 Max: 99.72
Current: 6.04
During the past 13 years, TTK Healthcare's highest ROE % was 99.72%. The lowest was 4.92%. And the median was 9.68%.
BOM:507747's ROE % is ranked better than 50.05% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs BOM:507747: 6.04
TTK Healthcare (BOM:507747) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
TTK Healthcare ROE % Related Terms
TTK Healthcare ROE % Historical Data
* Premium members only.
The historical data trend for TTK Healthcare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, TTK Healthcare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTK Healthcare ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTK Healthcare's ROE % distribution charts can be found below:
* The bar in red indicates where TTK Healthcare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
TTK Healthcare (BOM:507747) has a ROE % of 7.81% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on TTK Healthcare and its competitors. This is 19% below median its historical median of 9.68. Over the past decade, TTK Healthcare's ROE % has ranged from 4.92 to 99.72. According to the industry distribution chart, TTK Healthcare ranks #467 out of 935 companies in the Drug Manufacturers industry, placing it in the top 49.9%.
Is TTK Healthcare's ROE % too high?
TTK Healthcare's current ROE % of 7.81% is 19% below median its 10-year median of 9.68. Over the past 10 years, this metric has ranged from a low of 4.92 to a high of 99.72. The Drug Manufacturers industry median ROE % is 6.00. TTK Healthcare's value of 7.81% is 30.2% above this industry median. Based on the distribution chart, TTK Healthcare ranks #467 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TTK Healthcare has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTK Healthcare's ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, TTK Healthcare ranks #467 out of 935 companies for ROE %. This puts TTK Healthcare in the upper half of its industry. The industry median ROE % is 6.00. TTK Healthcare's value of 7.81% is 30.2% above this benchmark. Historically, TTK Healthcare's own ROE % has ranged from 4.92 to 99.72 over the past decade. While the company's 10-year median is 9.68 vs. the industry median of 6.00, TTK Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTK Healthcare's current ROE % of 7.81% is 30.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on TTK Healthcare and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTK Healthcare's current ROE % is 7.81%, which is 19% below median its own 10-year median of 9.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTK Healthcare stock overvalued right now?
Based on GuruFocus' analysis, TTK Healthcare (BOM:507747) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹1,452.52, compared to a current price of ₹920.00 — trading 36.7% below its estimated fair value. The current ROE % is 7.81%, which is 19% below median its 10-year median of 9.68 and 30.2% above the Drug Manufacturers industry median of 6.00. TTK Healthcare's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For TTK Healthcare (BOM:507747), the current ROE % is 7.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTK Healthcare (BOM:507747) Overvalued in 2026?
Based on GuruFocus' analysis, TTK Healthcare stock appears to be undervalued.
The current stock price of ₹920.00 is trading 36.7% below its estimated GF Value™ of ₹1,452.52.
GuruFocus considers TTK Healthcare to be Significantly Undervalued.
Key valuation signals for BOM:507747:
ROE %: 7.81% (19% below median its 10-year median of 9.68)
GF Value™: ₹1,452.52 vs. price of ₹920.00 (36.7% below fair value)
Industry Position: 30.2% above the Drug Manufacturers median (#467 of 935)
No single metric tells the full story. See the BOM:507747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTK Healthcare Ltd is an Indian pharmaceutical company. The company's operating segment includes Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods Division, and Others. Its Animal Welfare segment includes products for both Human and Veterinary use. The Consumer Products comprises of marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners and others. Protective Devices comprises of manufacturing and marketing of Male Contraceptives and other allied products. It generates maximum revenue from the Pharmaceuticals segment. Geographically, it derives a majority of revenue from India.
72GF Score
Get the complete analysis for BOM:507747
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507747 has been successfully added to your 
